High-performance liquid chromatography of HIV protease inhibitors in human biological matrices

被引:28
作者
Aarnoutse, RE
Wissen, CPWGMVV
Underberg, WJM
Kleinnijenhuis, J
Hekster, YA
Burger, DM
机构
[1] Univ Nijmegen, Med Ctr, Dept Clin Pharm, NL-6500 HB Nijmegen, Netherlands
[2] Univ Utrecht, Fac Pharm, Dept Pharmaceut Anal, NL-3584 CA Utrecht, Netherlands
来源
JOURNAL OF CHROMATOGRAPHY B | 2001年 / 764卷 / 1-2期
关键词
reviews; protease inhibitors;
D O I
10.1016/S0378-4347(01)00344-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Methods for HPLC analysis of protease inhibitors (Pls) in human biological matrices were reviewed. Assays have been developed for analysis of single PIs or for simultaneous measurement of multiple PIs in plasma-serum, saliva, cerebrospinal fluid and semen. Liquid-liquid extraction was most often applied for sample pretreatment but solid-phase extraction and protein precipitation were used as well. Reversed-phase or ion-pair chromatography have been used to separate PIs. Detection of Pls should be sensitive enough for quantitation of plasma concentrations below trough levels of single Pls, or below proposed therapeutic thresholds for Pls. The large majority of assays employs UV detection. As the potential for interferences is large, the selectivity of every method should be evaluated properly. The available high-performance liquid chromatography (HPLC) methods have been applied in clinical pharmacokinetic studies and for therapeutic drag monitoring of Pls. Participation in an interlaboratory quality control program is recommended for every laboratory engaged in the bioanalysis of PIs. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:363 / 384
页数:22
相关论文
共 84 条
  • [1] AARNOUTSE R, 2001, 8 C RETR OPP INF CHI
  • [2] Indinavir concentrations and antiviral effect
    Acosta, EP
    Henry, K
    Baken, L
    Page, LM
    Fletcher, CV
    [J]. PHARMACOTHERAPY, 1999, 19 (06): : 708 - 712
  • [3] Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors
    Acosta, EP
    Kakuda, TN
    Brundage, RC
    Anderson, PL
    Fletcher, CV
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 : S151 - S159
  • [4] [Anonymous], 2000, PRODUCT MONOGRAPH
  • [5] [Anonymous], 1996, MERCK INDEX ENCY CHE
  • [6] Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography
    Aymard, G
    Legrand, M
    Trichereau, N
    Diquet, B
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2000, 744 (02): : 227 - 240
  • [7] Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection
    Back, DJ
    Khoo, SH
    Gibbons, SE
    Barry, MG
    Merry, C
    [J]. THERAPEUTIC DRUG MONITORING, 2000, 22 (01) : 122 - 126
  • [8] Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients
    Baede-van Dijk, PA
    Hugen, PWH
    Verweij-van Wissen, CPWGM
    Koopmans, PP
    Burger, DM
    Hekster, YA
    [J]. AIDS, 2001, 15 (08) : 991 - 998
  • [9] Nelfinavir - An update on its use in HIV infection
    Bardsley-Elliot, A
    Plosker, GL
    [J]. DRUGS, 2000, 59 (03) : 581 - 620
  • [10] Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
    Barry, M
    Mulcahy, F
    Merry, C
    Gibbons, S
    Back, D
    [J]. CLINICAL PHARMACOKINETICS, 1999, 36 (04) : 289 - 304